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Background: Olfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we
retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom
computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of
radiotherapy in the light of recent advanced technology and chemotherapy.
Methods: Seventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients
were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or
chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy
preoperatively.
Results: The median follow-up time was 95 months (range 8–173 months). The 5-year overall survival (OS) and
relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had
recurrence with the median time to recurrence of 59 months (range 7–115 months). Late adverse events equal to
or above Grade 2 in CTCAE v4.03 were observed in three patients.
Conclusion: Multimodal therapy including radiotherapy with precise treatment planning based on CT simulation
achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with
ONB.
Keywords: Olfactory neuroblastoma, Computed tomography, Three-dimensional conformal radiotherapy, Late
adverse effectIntroduction
Olfactory neuroblastoma (ONB), or esthesioneuroblas-
toma, is a rare tumor originating from olfactory epithe-
lium. In a meta-analysis of studies published from 1990
through 2000, the cases of 390 patients were reported in
26 studies, and the averaged overall and disease-free sur-
vival rates at 5 years were 45% and 41%, respectively [1].
In ONB patients with metastases in cervical lymph
nodes (on average 5% of the total), the survival rate was* Correspondence: ronimaru@pop.med.hokudai.ac.jp
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therapy was suggested to be the optimum approach to
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and 2006 there were 511 patients in the Surveillance,
Epidemiology, and End Results (SEER) database, which
collects cancer incidence and survival data from cancer
registries that are population-based and cover approx.
26% of the United States population [2]. Those authors
showed that the 5-year overall survival stratified by
treatment modality was 73% for surgery with radiother-
apy, 68% for surgery only, 35% for radiotherapy only,is is an Open Access article distributed under the terms of the Creative
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that surgery with radiotherapy is the optimal strategy.
However, a standard strategy of treatment for ONB has
not been established, and the optimal radiotherapy dose,
the exact role of chemotherapy, and the effectiveness of
elective neck dissection are yet to be confirmed. Because of
the low incidence of ONB, it is difficult to conduct pro-
spective trials to test new treatments. Retrospective studies
can still be used to investigate treatment efficacy and
toxicities.
In our hospital, precise simulations using computed
tomography (CT) and three-dimensional dose calculation
have been used in the radiotherapy for all head and neck
cancer patients since the 1980s [3,4]. Since 1992, we have
also used the clinical target volume (CTV) delineated slice
by slice using 5-mm-thick slices from CT images, and pa-
tients have been treated with three-dimensional conformal
technologies. In the present study, we retrospectively in-
vestigated the patients with ONB who were treated with
the CT simulation. The purpose of this study was to
analyze the relationship between treatment modalities,
survival, tumor control, and the acute and late toxicity of
patients treated for ONB with radiotherapy with or with-
out surgery or chemotherapy.
Materials and methods
Patients
The Institutional Review Board at Hokkaido University
Hospital approved this retrospective study in May 2013.Table 1 Patient Characteristics and Treatments
Patient No. Gender Age Kadish stage LN meta Treatment
1 F 22 B – Surgery + Postop
2 M 59 B – Surgery + Postop
3 F 72 B – Surgery + Postop
4 M 53 C – Surgery + Postop
5 F 66 C RPN Surgery + Postop
6 M 63 C – PreopRT + Surger
7 M 55 C – NAC + Surgery +
8 F 71 C – NAC + Surgery +
9 F 43 C – NAC + Surgery +
10 M 37 C – NAC + Surgery +
11 M 66 C – NAC + Surgery +
12 F 44 C – NAC + Surgery +
13 M 46 C – Surgery + Chemo
14 M 24 C – NAC + definitive
15 F 67 C ILCN NAC + definitive
16 M 70 C – NAC + definitive
17 M 76 C – definitive RT + Ch
Abbreviations: RPN (retropharyngeal node), ILCN (ipsilateral cervical node), PostopR
(neoadjuvant chemotherapy), TR (total resection), STR (subtotal resection), PR (parti
(etoposide), CADO/CVP (cisplatin, cyclophosphamide, vincristine, etoposide and doxSeventeen patients with ONB were treated with defini-
tive intent with radiotherapy at the Department of
Radiotherapy, Hokkaido University Hospital between
July 1992 and June 2013. We retrospectively reviewed
their medical records including the initial diagnosis,
tumor extension, treatment modalities and follow-up,
and we used demographic information collected up until
September 2014. The patient characteristics are presented
in Table 1. All patients had a pathological diagnosis.
The median age of the patients at diagnosis was
59 years (range, 22–76 yrs). Ten of the 17 patients were
male and seven were female. According to the Kadish
classification, three patients were classified as stage B
(paranasal sinus involved) and 14 patients were classified
as stage C (extension beyond paranasal sinus). There
was no patient with stage A ONB. Lymph node metasta-
ses were observed in two patients at initial diagnosis:
one patient had retropharyngeal lymph node (RPN) me-
tastasis and the other had ipsilateral cervical node
metastasis.
Treatments
The patients’ treatments are summarized in Table 1. Five
patients were treated with surgery and postoperative
radiotherapy. One patient was treated with preoperative
radiotherapy and surgery. Six patients were treated with
neoadjuvant chemotherapy (NAC), surgery, and postoper-
ative radiotherapy. One patient was treated with surgery
followed by chemotherapy and sequential postoperativeSurgery Chemotherapy Radiation dose
RT TR – 65Gy/26Fr
RT PR – 60Gy/30Fr
RT STR – 50Gy/25Fr
RT STR – 56Gy/28Fr
RT TR – 65Gy/26Fr
y – 40Gy/20Fr
PostopRT STR ICE 1 cycle 65Gy/26Fr
PostopRT TR ICE 1 cycle 60Gy/30Fr
PostopRT TR ICE 5 cycle 60Gy/30Fr
PostopRT TR ICE 5 cycles 60Gy/30Fr
PostopRT TR CDDP 60Gy/24Fr
PostopRT STR CDDP + ETP 60Gy/30Fr
+ PostopRT PR ICE 2 cycles 66Gy/33Fr
RT – CADO/CVP 3 cycle 54Gy/27Fr
RT – ICE 2 cycles 66Gy/33Fr
RT – CDDP 1 cycles + ICE 2 cycles 65Gy/26Fr
emo – ICE 2 cycles 65Gy/26Fr
T (postoperative radiotherapy), PreopRT (preoperative radiotherapy), NAC
al resection), ICE (Ifosfamide, cisplatin and etoposide), CDDP (cisplatin), ETP
orubicin).
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definitive radiotherapy. One patient was treated with de-
finitive radiotherapy followed by chemotherapy.Surgery
We defined ‘total resection’ as no residual tumor after
surgery, ‘subtotal resection’ as resected macroscopic
tumor but microscopic residual tumor, and ‘partial re-
section’ as macroscopic residual tumor. Six, four, and
two patients underwent total, subtotal, and partial resec-
tions, respectively.
Three patients with stage B ONB underwent endoscopic
sinus surgery (ESS) (two patients) or tumor resection as
Denker’s operation (one patient). One patient with stage B
ONB who was treated with ESS and postoperative irradi-
ation underwent a biopsy from the cribriform plate on the
day the radiotherapy was completed and residual tumor
was observed; skull base surgery was thus performed for
this persistent disease.
Ten patients with stage C ONB underwent a radical
resection combining both otolaryngologic and neurosur-
gical resection. No cervical lymph node dissection was
performed in any patient.
Chemotherapy
All three patients with stage B ONB were treated with
surgery and postoperative radiotherapy without chemo-
therapy. Among the 14 patients with stage C disease,
three were treated without chemotherapy; the combin-
ation of surgery and postoperative radiotherapy was per-
formed for two patients, and preoperative radiotherapy
and surgery was performed for one patient.
Six patients with stage C disease were treated with
NAC followed by surgery and postoperative radiother-
apy. Four of these patients were treated with the ICE
(ifosfamide, cisplatin and etoposide) regimen and the
other two patients were treated with only cisplatin or
cisplatin and etoposide. One patient was treated with
surgery and postoperative sequential chemoradiotherapy.
In this patient, only the intracranial lesion was resected,
followed by postoperative chemotherapy (ICE regimen
in two cycles) and postoperative irradiation to cranial
and nasal lesions.
Three patients were treated with a combination of NAC
and radiotherapy without surgery. All were treated with
chemotherapy followed by radiotherapy. The regimen
of chemotherapy was ICE in two cycles for one patient,
carboplatin in one cycle and ICE in two cycles for one
patient and CADO/CVD (cisplatin, cyclophosphamide,
vincristine, etoposide and doxorubicin) regimen in three
cycles for one patient. The other patient was treated with
definitive radiotherapy followed by chemotherapy (ICE
regimen in two cycles).Radiotherapy
All patients were immobilized with a thermoplastic mask
in supine position at the time of simulation and irradi-
ation. The contrast-enhanced or plain planning CT was
obtained in five and in twelve patients respectively. The
planning CT and MRI fusion was used in four patients.
The radiation delivery was three-dimensional conformal
radiotherapy (3DCRT) in 16 patients and intensity-
modulated radiation therapy (IMRT) in one patient. X-ray
energy was 6 MV in 14 patients and 10 MV in two pa-
tients. One patient was treated with Co-60 initially and
with 10 MV X-ray in boost irradiation. Electron beams
with adequate energy were additionally used with the pho-
ton beams when the dose to the tumor using X-rays was
insufficient to avoid organs at risk such as the eye or brain.
Electron beams were typically used for the ethmoid or
frontal sinus.
The CTV included primary tumor or tumor bed and
postoperative resection cavity in postoperative cases, nasal
cavity, ethmoid bone and sphenoid bone in 15 patients
treated with 3DCRT. In addition, ipsilateral or bilateral
maxillary sinuses were included in four and one patients
respectively. One patient with RPN metastasis, who
underwent a resection of the primary lesion, was then irra-
diated only for the RPN with 65 Gy in 26 fractions.
In one patient treated with IMRT, the CTV consisted
of primary tumor identified in MRI obtained before and
after neoadjuvant chemotherapy, nasal cavity, ethmoid
bone, bilateral maxillary sinus and bilateral RPN and
upper jugular lymph node (level II) regions.
The fraction size was 2.0 Gy or 2.5 Gy. When 2.5 Gy
was used, the irradiation delivery was done 4 times per
week. When 2.0 Gy was used, irradiation delivery was
done 5 times per week.
Postoperatively, the planned doses were 50 to 66 Gy in
2 Gy or 2.5 Gy per fraction. In one patient with pre-
operative radiotherapy, the radiation dose was 40 Gy in
20 fractions.
There were three patients treated with sequential che-
moradiotherapy. The radiation dose was 65 Gy in 26
fractions after carboplatin in one cycle and ICE in two
cycles in one patient. In one patient with CADO/CVD
in three cycles, 54 Gy in 27 fractions was used. One pa-
tient with ipsilateral cervical node metastasis was treated
with ICE in two courses and then irradiated at the primary
site with 66 Gy in 33 fractions; the involved cervical
lymphatic region was irradiated with 40 Gy in 16 fractions.
In addition, a stereotactic boost with 28 Gy in 4 fractions
to the sphenoid bone and 10 Gy in 4 fractions to the eth-
moid sinus was performed for this patient. The overall
treatment time for radiotherapy ranged from 40 to 67 days
(median 44 days).The radiotherapy treatment planning
systems were a Focus or Xio (Computerized Medical Sys-























Figure 2 Kaplan-Meier plot of relapse-free survival.
Mori et al. Radiation Oncology  (2015) 10:88 Page 4 of 9(NEC Corp., Tokyo) in three patients, the Eclipse (Varian
Medical Systems, Palo Alto, CA) in two patients for the
3DCRT, and the Pinnacle (Philips Healthcare, Best, The
Netherlands) in two patients for the 3DCRT and IMRT.
Statistical analysis
Adverse effects of radiotherapy were evaluated based on
the NCI Common Terminology Criteria for Adverse
Events (CTCAE) version 4.03. We retrospectively graded
late adverse effects as the most severe one until last avail-
able consultation. Overall survival (OS) and relapse-free
survival (RFS) were estimated using the Kaplan-Meier
method. The period of relapse was defined as the time be-
tween the initial diagnosis and relapse or death, whichever
occurred first. Statistical analyses were performed using
JMP software, version 11.0.0 (SAS Institute, Cary, NC).
The p-values lower than 0.05 were considered significant.
Results
The median follow-up time was 95 months (range 8–173
months). The 5-year OS was 88% (95% confidence interval
[CI] 63.2% − 97.0%) and the 5-year RFS was 74% (95%CI
46.6% − 89.9%). There was no significant difference be-
tween the Kadish stage B and C patients in OS (p = 0.303,
Figure 1) or RFS (p = 0.214, Figure 2).
Five patients, all of whom had stage C disease, had re-
currence. The median time to recurrence was 59 months
(range 7–115 months). The pattern of recurrence was
intracranial recurrence in two patients, ipsilateral cer-
vical node metastasis in two patients, and spinal dissem-
ination in one patient. All of them were out of radiation
field or distant metastasis. The patient who suffered
from spinal dissemination died 1 month after the diag-
nosis of dissemination. This patient received NAC fol-
lowing IMRT. One patient with ipsilateral cervical node
metastasis died 18 months after the diagnosis of recur-
rence without no salvage treatment. This patient was



















Figure 1 Kaplan-Meier plot of overall survival.chemotherapy. The other three patients survived more
than 24 months (24, 47 and 101 months, respectively)
from the time of recurrence by salvage treatments such
as surgical resection or radiotherapy. Ten patients (eight
of whom were treated with surgery and two who were
not) had no relapse. For two other patients, it is un-
known whether they had disease or not with follow-up
periods of 17 and 146 months.
Acute adverse effects such as radiation dermatitis, mu-
cositis of nasal mucosa, and conjunctivitis were within
Grade 1–2 and tolerable in all patients. One patient was
affected with intracranial epidural abscess, when radio-
therapy was performed till 36 Gy and radiotherapy was
suspended during 13 days. One patient died 81 days
after the completion of radiotherapy and one patient
was followed up in another institution after the comple-
tion of radiotherapy, so 15 out of the 17 patients were
eligible for long-term toxicities evaluation. Late adverse
effects were observed in three patients. Three patients
showed abnormal findings thought to be radiation injury
at the frontal and left temporal lobes, the frontal and bilat-
eral temporal lobes, and the left frontal lobe in follow-up
brain MRI at 23, 47 and 57 months after radiotherapy, re-
spectively, but they showed no symptoms (Figure 3).
Late adverse effects equal to or above Grade 2 in CTCAE
v4.03 were observed in all of these patients; two patients
showed Grade 2 hypopituitarism such as hypothyroidism
or adrenal insufficiency at 75 and 103 months after the
completion of radiotherapy. One of these patients was pre-
scribed 66Gy in 33 fractions with a stereotactic boost to
the ethmoid sinus with 10 Gy in four fractions and to the
sphenoid bone with 28 Gy in four fractions (patient 13).
The other patient was prescribed 65 Gy in 26 fractions
(patient 1), and the dose to the pituitary sinus was esti-
mated as 52 to 62 Gy in 26 fractions from the dose distri-
bution. This patient also suffered from Grade 4 glaucoma,
retinopathy, and vitreous hemorrhage and needed oph-
thalmological intervention. The maximum dose to the eye
Figure 3 Coronal view of follow-up MRI 10 years after radiotherapy
(patient 1). Focal enhancement at the base of the frontal lobe was
observed. This finding disappeared in follow-up MRI after 9 months.
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tribution (Figure 4). This patient treated with X-ray and
electron beam, and the radiation injury occurred in theFigure 4 Dose distribution at the level of orbit (patient 1).area that matched the field of X-ray and electron beam.
A follow-up MRI and a fundus photograph of the pa-
tient’s left eye 10 years after the radiotherapy are shown
in Figure 5 and Figure 6.
The other patient suffered from the necrosis of frontal
bone 33 months after complete of radiotherapy and
needed necrotic bone removal (patient 9). She was pre-
scribed 60 Gy in 30 fractions. The necrotic part of frontal
bone was included in radiation fields and maximum dose
of it was about 62 Gy in 30 fractions from the dose vol-
ume histogram. No hot spot above 62 Gy within frontal
bone was observed in the dose distribution.
Discussion
Eich et al. reported that the 5-year OS was 64% in an
ONB population of 14 stage B patients and 33 stage C pa-
tients with multimodality therapy including surgery, radio-
therapy, and chemotherapy [5]. Ozsahin et al. reported
that the OS at 5 years was 52% (95% CI 34%–70%) in stage
C patients with multimodality therapy including surgery,
radiotherapy and chemotherapy [6]. In the present study,
the OS and RFS at 5 years were 88% and 74%, respectively.
Grade 2 or above late radiation toxicities occurred in three
patients. These OS and RFS values are comparable to
those of previous reports and tend to be higher than previ-
ously reported outcomes (Table 2). Our cohort ranged
over more than 20 years and anti-cancer treatment has
dramatically changed throughout these periods: surgical
technique improvements and extended use of chemother-
apy may have also modified the patient outcomes. Though
Figure 5 Axial view of follow-up MRI 10 years after radiotherapy
(patient 1). Retinopathy of the left eye was observed.
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ning using CT with multimodal therapy are encouraging,
it is difficult to come to the conclusion that it is only due
the role of the 3DCRT.
We used 50 to 66 Gy as postoperative radiotherapy,
40 Gy as preoperative radiotherapy, and 54 to 66 Gy in
the setting of sequential chemoradiation therapy. Diaz
et al. reported a mean radiation dose of 56.9 Gy (range
50.0 − 67.2 Gy) in a postoperative setting [7]. Bacher et al.
reported the mean dose of radiation as 53.13 Gy (medianFigure 6 Fundus photograph of the left eye 10 years after
radiotherapy (patient 1). Exudate and vitreous hemorrhage
are observed.50 Gy, range 50–60 Gy) for the preoperative setting and
54.57 Gy (median 55 Gy, range 45–60 Gy) for the post-
operative setting [8]. Other studies described postopera-
tive doses ranging from 55 to 65 Gy, preoperative doses
at 50 Gy, and inoperative patients receiving up to 70 Gy
[9,1]. Because of the rarity of ONB, it is still difficult to
establish the optimal radiation dose.
In our study, eleven of the 17 patients received chemo-
therapy, and nine of these eleven patients received NAC.
Kim et al. reported that two of 11 patients with ONB
who received NAC consistent with etoposide, ifosfamide
and cisplatin showed complete responses and seven of
11 patients showed partial responses [10]. Mishima et al.
reported the results of NAC and radiotherapy with or
without peripheral blood stem cell support or surgery
[11]. They reported that eight of 12 patients with ONB
showed complete responses after the treatment.
Noh et al. reported that failure in a cervical node did
not occur in their ONB patients who were treated with
systemic chemotherapy without elective cervical nodal
irradiation [12]. However, Elkon et al. reported the re-
sults of surgery and radiotherapy without chemotherapy
in which the 5-year OS was 75%, 60% and 41% for Kad-
ish stage A, B and C patients, respectively [13]. Gruber
et al. reported that the DFS at 5 years was 70% without
chemotherapy [14]. Despite the small number of patients
in each study and some biases including technical ad-
vancement, the results of the treatment with chemother-
apy seem to be better than those achieved without
chemotherapy. Our present findings do not contradict
the hypothesis that the addition of chemotherapy may
improve survival in patients with ONB treated with
radiotherapy.
Although elective nodal irradiation was not used in
the present patient series, only two patients experienced
ipsilateral cervical node metastases (27 and 59 months
after radiotherapy). One patient (patient 5) was initially
diagnosed with RPN metastasis and only the primary le-
sion was resected. She then underwent irradiation only
for the RPN with 65 Gy in 26 fractions without chemo-
therapy. The other patient (patient 17) was treated with
definitive radiotherapy with 65 Gy in 26 fractions
followed by chemotherapy. Some investigators have pro-
posed the necessity of elective nodal irradiation.
Demiroz et al. reported that elective nodal failure oc-
curred in seven of 26 patients and recommended the use
of elective nodal irradiation [15]. Only two patients re-
ceived chemotherapy in that study. However, Noh et al.
reported that no cervical failure was observed in nine
patients treated with a multimodal approach including
systemic chemotherapy. They concluded omitting elect-
ive nodal may be an option when patients are treated
with a combination of radiotherapy and chemotherapy
[12]. In our study, there was one patient with cervical
Table 2 Studies reporting treatment outcomes for ONB
Author Year Period Patients (n) Treatment Follow up (mo) 5-year OS Other Survival (yr)
Gruber [14] 2002 1980-2001 28 Surgery + Pre-/PostopRT or RT +/− CTX 68 77% DFS 70% (5 yr)
Eich [5] 2003 1979-2001 47 Surgery only, Surgery + PostopRT, RT +/− CTX or multimodality therapy 65 64% EFS 50% (5 yr)
Diaz [7] 2005 1979-2002 30 Surgery only, Surgery + Pre-/PostopRT or RT +/− CTX 87 89% RFS 69% (5 yr)
Ozsahin [6] 2010 1971-2004 77 Surgery only, Surgery + RT, RT +/− CTX or multimodality therapy 72 64% DFS 57% (5 yr)
Platek [2] 2011 1973-2006 511 Surgery only, Surgery + RT, RT only or neither surgery nor RT – 73% Surgery + RT, –
68% Surgery only,
35% RT only,
26% neither surgery nor RT
Modesto [9] 2013 1998-2010 43 multimodality therapy 77 65% PFS 57% (5 yr)
Present study – 1992-2013 17 Surgery + PostopRT, PreopRT + Surgery or multimodality therapy 95 88% RFS 74% (5 yr)











Mori et al. Radiation Oncology  (2015) 10:88 Page 8 of 9nodal recurrence among the eleven patients who received
chemotherapy. Although the small number of patients
makes it difficult to make any definite conclusions, we
cannot exclude the potential role of elective nodal irradi-
ation in the eradication of microscopic lymph node metas-
tasis even when systemic chemotherapy is used.
Glaucoma, retinopathy and vitreous hemorrhage oc-
curred together in one patient in our study. This patient
was treated with 3DCRT using X-rays and electron beam.
It is possible that these late toxicities resulted from the un-
certainty in field matching. In order to reduce these late
toxicities further in this patient, IMRT or proton beam
therapy (PBT) may have been helpful. One of our patients
(patient 12) received IMRT, and he experienced spinal dis-
semination and died 81 days after the completion of radio-
therapy, and thus any late toxicities of this patient could
not be evaluated. The efficacy of IMRT for tumor in nasal
cavity and paranasal sinuses has been reported [16,17]. In
a subset analysis of patients with tumors of the paranasal
sinuses and nasal cavity treated with IMRT in a recent
investigation by Wiegner et al., the 2-year local regional
control rate and the 2-year OS of ONB were 86% and
100% respectively. They also reported that six (11.5%)
out of 52 patients had late toxicity equal to or above
Grade 3 including corneal ulcer in one patient [16].
Dirix et al. retrospectively compared toxicities between
groups treated with IMRT and those treated with
3DCRT postoperatively for tumors of the paranasal si-
nuses or nasal cavity. They found no radiation-induced
visual impairment nor Grade 3 or 4 late toxicity in 39 pa-
tients who received IMRT whereas six (15.8%) radiation-
induced retinopathy resulting in mild to moderate visual
impairment in 38 patients in the 3DCRT group [17].
PBT may also contribute to a reduction of late toxicities
and may help reduce the risk of secondary malignancy
compared to IMRT. Nishimura et al. reported the prelimin-
ary results of PBT: no Grade 3 or above late toxicities were
observed other than skin reaction, and one patient with
Kadish C experienced liquorrhea after tumor shrinkage
[18]. Nichols et al. and Herr et al. also reported results of
multimodality therapy including PBT [19,20]. They ob-
served nine Grade 3 complications and one case of Grade 4
radiation-induced optic neuritis with an average follow-up
of 73 months. Technical advances in radiation oncology
such as IMRT and PBT can result in less toxicity in the
treatment of ONB.
Several investigators reported that recurrence occurs
long after the completion of ONB treatment. Loy et al.
reported the mean relapse interval of 6 years [21]. Gruber
et al. reported that five of 28 patients had recurrence over
60 months after the completion of treatment [14]. Bacher
et al. reported that the median time from diagnosis to re-
currence was 57 months [8]. In our study, the median
follow-up time was 95 months (range 8–173 months).Although it was not possible to identify the actual cause of
death in three of the patients in our series, the follow-up
time was one of the longest in the literature. Long-term
follow-ups are necessary for the evaluation of ONB treat-
ments in prospective settings.
In this study, we retrospectively reviewed medical re-
cords. Some kinds of adverse effects, especially symptom-
atic or low grade ones, can be missed if they were not
written in medical records. Therefore, we may underesti-
mate the incidence of adverse effects of radiotherapy. In
addition, the small number of patients without control
group and treatment heterogeneity makes interpretation
of results very difficult.
Nowadays 3DCRT is very common treatment tech-
nique, but because of low incidence of ONB, retrospective
studies as this present study using 3DCRT can still be
meaningful to investigate treatment efficacy and toxicities
of ONB and we can expect the improvement of treatment
outcome and less toxicity hereafter.
In conclusion, it is suggested that multimodal therapy
including radiotherapy with precise treatment planning
based on CT simulation was effective for ONB in terms
of local control and overall survival. More advanced ra-
diation technique such as IMRT and PBT providing
more optimal dose delivery can reduce late toxicities
and improve treatment outcome of ONB.
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